ReviewCurrent neurology and neuroscience reports2024
Novel Approaches to the Treatment of Idiopathic Intracranial Hypertension.
Review in Current neurology and neuroscience reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.The journal of headache and pain · 2025Pooled it
- Effectiveness of Topiramate Versus Acetazolamide in the Management of Idiopathic Intracranial Hypertension: ASystematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Evaluation of Racial, Ethnic, and Socioeconomic Disparities in Idiopathic Intracranial Hypertension.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2025Article
- Current Understanding of the Pathophysiology of Idiopathic Intracranial Hypertension.Current neurology and neuroscience reports · 2025Review
- Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.Annals of clinical and translational neurology · 2025Article
- Stenting versus medical treatment for idiopathic intracranial hypertension based on a propensity score matching method.Quantitative imaging in medicine and surgery · 2025Article
- Efficacy and Safety of Optic Nerve Sheath Fenestration for Idiopathic Intracranial Hypertension. A Subgroup-Focused Systematic Review and Meta-Analysis.ASIDE internal medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIdiopathic intracranial hypertension (IIH) typically affects women of childbearing age, is associated with recent weight gain, and can result in debilitating headache as well as papilledema that can cause vision loss. There have been advances in the medical and surgical treatment of affected patients with IIH that can improve outcomes and tolerability of therapy. RECENT
findingsMedical treatment with agents that lower intracranial pressure through pathways other than carbonic anhydrase inhibition are being developed, and medically-directed weight loss as well as bariatric surgery now may be considered as primary therapy. New surgical options including venous sinus stenting have shown efficacy even with cases of severe vision loss. Our treatment options for IIH patients are becoming more diverse, and individualized treatment decisions are now possible to address specific components of the patient's disease manifestations and to lead to IIH remission.
Indexed as
Identifiers
38864967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.